Journal article
Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation
Journal of oncology pharmacy practice, Vol.29(5), pp.1094-1102
07/01/2023
DOI: 10.1177/10781552221091282
PMID: 35369813
Abstract
Molecular tumor boards provide precision treatment recommendations based on cancer genomic profile. However, practical barriers limit their benefits. We studied the clinical utility of the precision medicine molecular tumor board (PMMTB) and described challenges with PMMTB implementation.
An observational cohort study included patients reviewed by the PMMTB between September 2015 to December 2017. Patients who had consented to the registry study were included. The primary endpoint of this study was time on treatment (ToT) ratio. Clinical utility was established if the primary endpoint had least 15% of patients achieving a ToT ratio of ≥1.3.
Overall, 278 patients were presented to the PMMTB and 113 cases were included in the final analysis. The PMMTB identified at least one nonstandard of care (SOC) clinically actionable mutation for 69.0% (78/113) of cases. In patients who received non-SOC treatment, 43.8% (7/16) achieved a ToT ratio of 1.3 or more (p < 0.001). Fifty-nine patients did not receive non-SOC recommendations. Reasons for not pursuing treatment included 35.6% having response to current treatment, 20.3% died prior to starting or considering PMMTB recommendations, 13.6% pursued other treatment options based on clinician discretion, another 10.2% pursued other treatment options because clinical trials recommended were not geographically accessible, 8.5% had rapid decline of performance status, 6.8% lacked of financial support for treatment, and 5.1% were excluded from clinical trials due to abnormal laboratory values.
The regional PMMTB non-SOC recommendations benefitted a majority of patients and additional processes were implemented to assist with non-SOC treatment accessibility.
Details
- Title: Subtitle
- Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation
- Creators
- Keng Hee Peh - University of KentuckyDaniel J Przybylski - Northwestern MedicineMichael J Fallon - University of Wisconsin HealthJason J Bergsbaken - University of Wisconsin HealthPaul R Hutson - University of Wisconsin–MadisonMenggang Yu - University of Wisconsin Carbone Cancer CenterDustin A Deming - University of Wisconsin–MadisonMark E Burkard - University of Wisconsin–Madison
- Resource Type
- Journal article
- Publication Details
- Journal of oncology pharmacy practice, Vol.29(5), pp.1094-1102
- DOI
- 10.1177/10781552221091282
- PMID
- 35369813
- ISSN
- 1078-1552
- eISSN
- 1477-092X
- Language
- English
- Date published
- 07/01/2023
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984700649702771
Metrics
5 Record Views